Aspire-Lakewood Holdings Inc. (ASBP)
ASBP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K/A (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1847345/000149315226015737/0001493152-26-015737-index.htm. Net income: SEC 10-K/A (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ASBP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001847345 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Cayman Islands |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $6K |
| Net income | -$24.5M |
| Operating income | -$19.4M |
| Net margin | -394725.1% |
| Operating margin | -312016.9% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $1.0M |
| Total assets | $1.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1822.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-13 |
| Cash and burn | $12.2M cash; operating cash flow -$1.8M a quarter. | Report 2026-06-30 |
| Shares outstanding | 1,402,557 (2026-08-07); 49,525,970 a year earlier. 1y figure adjusted for split (1-for-40 overall). | Cover page 2026-08-07 |
| Reverse splits, 3 years | 1; latest 1-for-40 on 2026-01-16 | Source 2026-01-16 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2025-02-19 |
| Auditor | Turner, Stone & Company, L.L.P., Dallas, Texas, United States; changed auditors 3 times in 24 months | 8-K 4.01 2026-09-29 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $63K | -$1.3M | -$2.1M | $12.2M | No debt tags | $98K | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $28K | -$3.2M | -$3.0M | $5.9M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $4K | -$4.7M | -$928K | $1.0M | $1.4M | $6K | 10-K/A 2026-04-08 |
| Q3 2025 2025-09-30 | $2K | -$1.9M | -$1.1M | $1.9M | $8.5M | Needs four quarters | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | Not filed | -$2.0M | -$1.1M | $206K | $5.4M | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | -$15.9M | -$1.8M | $1.3M | $4.9M | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2024 2024-12-31 | Not filed | -$766K | $480K | $4K | $1.3M | Needs four quarters | 10-Q 2025-11-14 |
| Q3 2024 2024-09-30 | Not filed | -$216K | -$496K | $17K | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-1/A | 2026-04-10 |
| Latest annual report | 10-K/A | 2026-04-08 |
| Latest quarterly / interim | 10-Q | 2026-08-13 |
| Latest current report | 8-K/A | 2026-10-20 |
| Latest proxy | DEF 14A | 2026-05-08 |
Source: SEC EDGAR submissions feed, 230 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.0% |
| 1 month | +2.8% |
| 3 months | +18.3% |
| Year to date | +59.3% |
| 1 year | +100.2% |
| From 52-week high | -9.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| ASBPW | Aspire-Lakewood Holdings Inc. Warrant | $0.0117 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DARE | Dare Bioscience Inc. | $0.5842 | -11.13% | $11.5M |
| RADX | Radiopharm Theranostics Limited | $0.7676 | +1.00% | $11.1M |
| BIVI | BioVie Inc. | $1.08 | -4.42% | $11.6M |
| PTN | Palatin Technologies Inc. | $6.13 | -1.69% | $10.9M |
| LSTA | Lisata Therapeutics Inc. | $1.09 | -9.92% | $11.8M |
| HIND | Vyome Holdings Inc. | $1.53 | -3.16% | $10.7M |
| QNTM | Quantum Biopharma Ltd. Class B Subordinate Voting Shares | $1.44 | -10.56% | $12.2M |
| OPTH | Optimi Health Corp. Common Shares | $2.15 | -4.44% | $12.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier